ONLINE SUPPLEMENTARY MATERIAL

Supplementary Table S1. Baseline and time-varying predictors of failure to apply **T2T-REM** (<u>**according to CDAI and SDAI**</u>) during 2-year follow-up in the RA BIODAM Cohort.

	CDAI		SDAI	
	Baseline model OR (95% CI) (N=551)	Longitudinal model OR (95% CI) (N=540)	Baseline model OR (95% CI) (N=549)	Longitudinal model OR (95% CI) (N=540)
Age (years)	¥	¥	¥	1.01 (1.00; 1.01)
Gender (female)	**1.26 (1.05; 1.52)**	**1.30 (1.03; 1.64)**	**1.21 (1.01; 1.46)**	**1.28 (1.02; 1.60)**
Disease duration (years)	¥	¥	¥	¥
Education (years)	**0.97 (0.95; 0.99)**	**0.95 (0.93; 0.98)**	**0.96 (0.94; 0.98)**	**0.95 (0.93; 0.98)**
Number of comorbidities	¥	¥	¥	¥
Current smoker	†	†	†	†
Type of centre (academic)	**1.21 (1.02; 1.43)**	¥	†	†
RF positivity	†	¥	†	†
ACPA positivity	¥	**0.79 (0.64; 0.98)**	¥	**0.80 (0.65; 0.98)**
RF and/or ACPA positivity	¥	†	¥	¥
PGA (0-10)	¥	¥	¥	¥
PhGA (0-10)	†	¥	¥	¥
Swollen joint count (0-44)	†	**0.87 (0.85; 0.89)**	†	**0.88 (0.86; 0.90)**
Tender joint count (0-53)	¥	¥	¥	¥
ESR (mm/h)	†	¥	†	¥
CRP (mg/L)	¥	¥	†	¥
HAQ	**1.26 (1.12; 1.41)**	¥	**1.28 (1.14; 1.44)**	¥
Number of previous csDMARDs	¥	**1.13 (1.02; 1.24)**	¥	¥
Previous treatment with any csDMARD	¥	¥	¥	¥

†: not selected from the univariable analysis (p>0.20); ¥: not significant in the multivariable analysis (p>0.05). Country added as a covariate in all univariable models and in the final multivariable model. Final models also adjusted for type of treatment (csDMARDs and/or bDMARDs)

Supplementary Table S2. Baseline and time-varying predictors of failure to apply **T2T-LDA** (<u>**according to CDAI and SDAI**</u>) during 2-year follow-up in the RA BIODAM Cohort.

	CDAI		SDAI	
	Baseline model OR (95% CI) (N=538)	Longitudinal model OR (95% CI) (N=555)	Baseline model OR (95% CI) (N=538)	Longitudinal model OR (95% CI) (N=555)
Age (years)	¥	**1.01 (1.00; 1.02)**	¥	¥
Gender (female)	†	†	†	†
Disease duration (years)	¥	¥	¥	†
Education (years)	**0.97 (0.95; 0.99)**	¥	**0.97 (0.95; 1.00)**	¥
Number of comorbidities	¥	¥	¥	¥
Current smoker	†	†	†	†
Type of centre (academic)	¥	¥	¥	¥
RF positivity	¥	¥	¥	¥
ACPA positivity	**0.62 (0.51; 0.75)**	**0.62 (0.52; 0.46)**	**0.63 (0.51; 0.77)**	**0.64 (0.53; 0.78)**
RF and/or ACPA positivity	¥	¥	¥	¥
PGA (0-10)	¥	¥	¥	¥
PhGA (0-10)	¥	¥	¥	¥
Swollen joint count (0-44)	†	**0.97 (0.95; 0.99)**	†	**0.97 (0.95; 0.99)**
Tender joint count (0-53)	**1.02 (1.01; 1.03)**	**1.02 (1.01; 1.04)**	**1.02 (1.01; 1.03)**	**1.02 (1.01; 1.03)**
ESR (mm/h)	¥	†	†	†
CRP (mg/L)	¥	¥	†	†
HAQ	**1.18 (1.02; 1.36)**	¥	**1.20 (1.04; 1.39)**	**1.40 (1.22; 1.61)**
Number of previous csDMARDs	¥	¥	¥	¥
Previous treatment with any csDMARD	¥	¥	¥	¥

†: not selected from the univariable analysis (p>0.20); ¥: not significant in the multivariable analysis (p>0.05). Country added as a covariate in all univariable models and in the final multivariable model. Final models also adjusted for type of treatment (csDMARDs and/or bDMARDs)